Stockreport

Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson

Can-Fite Biopharma Ltd Sponsored ADR (Israel)  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF The study did not achieve its primary end point of median overall survival in the whole population of 78 patients, however, superiority in me [Read more]